Advancing Medical Product Development (AMPD) of the Clinical Translational Science Institute of SE Wisconsin
2019 FALL CTSA Program Meeting
September 26-27, 2019
Advancing Medical Product Development (AMPD) of The Clinical Translational Science Institute of SE Wisconsin
Optional Module Poster Abstract
The Clinical Translational Science Institute of SE Wisconsin (CTSI) consists of eight partner institutions. Our Optional Module, called Advancing Medical Product Development (AMPD) is a multi-institutional and community collaboration whose goal is to advance discoveries to new healthcare products by connecting and leveraging a network of shared development and commercialization resources throughout the innovation ecosystem in SE WI. CTSI institutions actively partner under the AMPD module through the Regional Intellectual Property Commercialization Network (RIPCN) and the Device and Drug Discovery Initiative (D3I). Comprised of technology transfer representatives from CTSI partner institutions, RIPCN partners with representatives from industry, government, state economic development offices and affiliated service providers. D3I is a consortium of Universities, focused on commercializing healthcare innovations. Together, RIPCN and D3I have delivered several successful projects under the AMPD module as described here.
Our continued goal is to strengthen the regional network of ideas, talent, and capital, by focusing on key nodes and connections in the regional healthcare innovation ecosystem. We will leverage and connect existing resources (nodes) that provide networking, business development, regulatory and IP training, as well as access to capital for startups. This aligns with the NCATS model of collaboration across and within CTSA hubs and development of thriving life science innovation eco-systems. Our AMPD module will deploy grant resources to: (a) strengthen key nodes, (b) foster key connections, and thereby (c) assist innovators navigate the ecosystem to commercialize and move healthcare innovations from bench to bedside, via licensing and startup companies. We will thus facilitate the translation of discoveries, increase the effectiveness of biomedical product development, and deliver life-saving products to the patients who need them.